Objective: This study was to investigate whether switching sulfonylurea to mitiglinide/voglibose could improve glycemic variability and endothelial dysfunction in patients with type 2 diabetes.
Methods:This was a single arm study of 6 Japanese patients with type 2 diabetes (n =6, 5 male, 72 ± 7 year-old). Patients with 0.25-1.0 mg of glimepiride (0.8 ± 0.3 mg) with HbA1c between 6.5-7.5% were enrolled and were switched from glimepiride to mitiglinide/voglibose (fixed-dose combination of mitiglinide 10 mg and voglibose 0.2 mg three times a day) for 3 months.Results: Mean amplitude of glycemic excursion (MAGE) was significantly decreased from 3.4 ± 1.3 to 1.6 ± 0.6 mmol/l (P = 0.014). Both fasting and postprandial FMD also significantly improved (5.3 ± 1.6 vs. 7.1 ± 1.7, P = 0.043 and 3.5 ± 1.5 vs. 5.2 ± 1.1, P = 0.043). The declines of insulin and C-peptide levels at 120 min were significantly correlated with the increase in postprandial FMD (r = -0.97, P = 0.013, and r = -1.00, P = 0.004).
Conclusions:Glycemic variability and endothelial dysfunction at fasting and postprandial states were improved by mitiglinide/voglibose and it may be through the attenuation of hyperinsulinemia.We focused on the potential of the combination treatment to ameliorate endothelial dysfunction due to reducing the postprandial hyperglycemia [9,10], because previous studies showed that each monotherapy of glinide and α-glucosidase inhibitor ameliorated endothelial dysfunction [11,12]. In this context, we conducted this pilot study to investigate whether switching from SU to mitiglinide/ voglibose could reduce the fluctuation of blood glucose, eventually decreasing in the hypoglycemic episodes and amelioration of endothelial dysfunction in patients with type 2 diabetes.
Subjects and methodsPatients with less than 1.0 mg of glimepiride (0.8 ± 0.3 mg) with HbA1c between 6.5-7.5% (n =6, 5 male, 72 ± 7 year-old) were enrolled. Two patients were treated with metformin and 1 patient with vildagliptin at the base line. The patients were switched from glimepiride to mitiglinide/voglibose (fixed-dose combination of mitiglinide 10 mg Murakami M (2017) Beneficial effect of combination therapy with mitiglinide and voglibose on fasting and postprandial endothelial dysfunction in patients with type2 diabetes: a pilot study